TREATING VASCULAR DISEASE AND COMPLICATIONS THEREOF
Administration of an antibody that specifically binds IL-1α is useful for reducing the chance or severity of a major adverse clinical event occurring in a mammalian subject having received or expected to receive surgical treatment for a stenosed blood vessel, and for reducing the change of restenosis occurring (or increasing the time until restenosis occurs) in a mammalian subject having received or expected to receive surgical treatment for a stenosed blood vessel.
1 . A method of reducing the chance of a major adverse clinical event occurring in a human subject having received or expected to receive surgical treatment for a stenosed blood vessel, the method comprising the step of repeatedly administering to the subject a 0.2 to 20 mg/kg dose of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an anti-interleukin-1alpha (anti-IL-1α) antibody at least until the chance of a major adverse clinical event occurring in the subject is reduced.
2 . The method of claim 1 , wherein the anti-IL-1α antibody is a monoclonal antibody.
3 . The method of claim 2 , wherein the monoclonal antibody is an IgG1.
4 . The method of claim 2 , wherein the monoclonal antibody comprises a complementarity determining region of MABp1.
5 . The method of claim 2 , wherein the monoclonal antibody is MABp1.
6 . The method of claim 1 , wherein at least 4 doses are administered to the subject.
7 . The method of claim 1 , wherein the pharmaceutical composition is administered to the subject biweekly.
8 . A method of reducing the chance of restenosis occurring in a human subject having received or expected to receive surgical treatment for a stenosed blood vessel, the method comprising the step of repeatedly administering to the subject a 0.2 to 20 mg/kg dose of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an anti-IL-1α antibody at least until the chance that the vessel will become restenosed is reduced.
9 . The method of claim 8 , wherein the anti-IL-1α antibody is a monoclonal antibody.
10 . The method of claim 9 , wherein the monoclonal antibody is an IgG1.
11 . The method of claim 9 , wherein the monoclonal antibody comprises a complementarity determining region of MABp1.
12 . The method of claim 9 , wherein the monoclonal antibody is MABp1.
13 . The method of claim 8 , wherein at least 4 doses are administered to the subject.
14 . The method of claim 8 , wherein the pharmaceutical composition is administered to the subject biweekly.